AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28062595 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg) before late scans
Number of subjects: 112
Study 28062595 — intervention group
Group type: EXPERIMENTAL
Intervention: Late scans (3 h after injection)
Number of subjects: 112
Study 28062595 — intervention group
Group type: COMPARATOR
Intervention: Early scans (1 h after injection)
Number of subjects: 112
Study 26016656 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnographic (PSG) recordings on Day 21 (D21) and Day 51 (D51) of the 70-day patrol
Number of subjects: 19
Study 26016656 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective assessments of sleep, sleepiness, mood, and anxiety on D21 and D51
Number of subjects: 19
Study 26016656 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cortisol levels taken after sleep
Number of subjects: 19
Study 23896980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 1 mg/kg
Number of subjects: 46
Study 23896980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 4 mg/kg
Number of subjects: 46
Study 23896980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 10 mg/kg
Number of subjects: 46
Study 23896980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab (all doses)
Number of subjects: 46
Study 23896980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 22321594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (n=81)
Number of subjects: 261
Study 22321594 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=75)
Number of subjects: 261
Study 22321594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (n=25)
Number of subjects: 261
Study 22321594 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 261
Study 22321594 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (n=194)
Number of subjects: 261
Study 18927241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant hydrochloride injection (3 mg/kg initially via 10-minute intravenous infusion followed by a second 2 mg/kg 10-minute infusion if atrial fibrillation persisted)
Number of subjects: 4
Study 18927241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant hydrochloride injection (1 or 2 infusions)
Number of subjects: 4
Study 18927241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant hydrochloride injection
Number of subjects: 4
Study 17335300 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine
Number of subjects: 0
Study 15033130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 55
Study 15033130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11206684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (5 to 200 mg)
Number of subjects: 1218
Study 11206684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 1218
Study 11206684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1218
Study 9795316 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS medications (epinephrine, atropine, bicarbonate, calcium, lidocaine)
Number of subjects: 773
Study 9795316 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 773
Study 9795316 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 773
Study 9795316 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate
Number of subjects: 773
Study 9795316 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 773
Study 9795316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 773
Study 7649749 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient care for decedents
Number of subjects: 914
Study 7649749 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care for nondecedents
Number of subjects: 914
Study 7649749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite patients
Number of subjects: 914
Study 7649749 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient nights and costs
Number of subjects: 914
Study 7649749 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 914
Study 2745500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride
Number of subjects: 0
Study 2745500 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 0
Study 237234 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 51
Study 237234 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 51
Study 237234 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized medical group
Number of subjects: 51
Study 30759221 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous denosumab 60 mg every 6 months for 3 years, then 7 years of open-label denosumab
Number of subjects: 45
Study 30759221 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous denosumab 60 mg
Number of subjects: 45
Study 28392436 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX-106 (2mg/day)
Number of subjects: 14
Study 28392436 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX-106 (8mg/day)
Number of subjects: 14
Study 28392436 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX-106 (16mg/day)
Number of subjects: 14
Study 28392436 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX-106 (all doses)
Number of subjects: 14
Study 24902868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 34
Study 23263473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets (3.5 mg/kg)
Number of subjects: 0
Study 23263473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets (5.25 mg/kg)
Number of subjects: 0
Study 23263473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21109557 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 25 mg subcutaneous injections twice weekly
Number of subjects: 132
Study 21109557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 19755091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2%
Number of subjects: 53
Study 19755091 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.2%
Number of subjects: 53
Study 17306906 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DC)
Number of subjects: 94
Study 17306906 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VC)
Number of subjects: 94
Study 14984382 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, metronidazole and clarithromycin (OMC)
Number of subjects: 0
Study 14984382 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole and placebo antimicrobials (OPP)
Number of subjects: 0
Study 14984382 — intervention group
Group type: COMPARATOR
Intervention: OMC vs. OPP
Number of subjects: 0
Study 11300383 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (ETO group)
Number of subjects: 30
Study 11300383 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (THIO group)
Number of subjects: 30
Study 11300383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 10492661 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole pulse therapy (1 week 400 mg daily, 3 months)
Number of subjects: 51
Study 10492661 — intervention group
Group type: COMPARATOR
Intervention: Continuous terbinafine dosing (250 mg daily, 3 months)
Number of subjects: 51
Study 1725023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 or 10 mg daily)
Number of subjects: 502
Study 6523394 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial synovial fluid (ASF) and its complexes (PVP-hyaluronate, PVP, cyclophosphamide, hydrocortisone, arteparone)
Number of subjects: 520
Study 6523394 — intervention group
Group type: COMPARATOR
Intervention: Kenalog or placebo
Number of subjects: 520
Study 30908754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapericardial (IP) Tranexamic Acid
Number of subjects: 97
Study 30908754 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) Tranexamic Acid
Number of subjects: 97
Study 29575637 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg daily
Number of subjects: 38
Study 29575637 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study 28089473 — intervention group
Group type: EXPERIMENTAL
Intervention: Box trainer
Number of subjects: 36
Study 28089473 — intervention group
Group type: COMPARATOR
Intervention: VR trainer
Number of subjects: 36
Study 23652351 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD plus adenoviral vectors encoding Mfn2
Number of subjects: 4
Study 23652351 — intervention group
Group type: COMPARATOR
Intervention: HFD
Number of subjects: 4
Study 23652351 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD plus adenoviral vectors
Number of subjects: 4
Study 23652351 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 4
Study 21365230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric ESSQ certification process
Number of subjects: 29
Study 20031692 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 1983
Study 20031692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1983
Study 17942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Data handling capacity establishment and monitoring through national and international collaboration
Number of subjects: 0
Study 17942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection and fieldwork supervision
Number of subjects: 0
Study 17942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Community advisory board involvement
Number of subjects: 0
Study 17942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa statistics for inter- and intra-observer agreement
Number of subjects: 0
Study 17942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical Errors of Measurement for anthropometric measurements
Number of subjects: 0
Study 17942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit trail analysis for error correction rates
Number of subjects: 0
Study 15110728 — intervention group
Group type: EXPERIMENTAL
Intervention: Human body stimuli (silhouettes and stick figures)
Number of subjects: 0
Study 15110728 — intervention group
Group type: COMPARATOR
Intervention: Control stimuli (object silhouettes, object stick figures, scrambled silhouettes of bodies, body parts, and objects)
Number of subjects: 0
Study 11567807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (120 cGy b.i.d.)
Number of subjects: 81
Study 11567807 — intervention group
Group type: COMPARATOR
Intervention: Accelerated-hyperfractionated radiotherapy (160 cGy b.i.d.)
Number of subjects: 81
Study 10326743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod (400 mg oral bottle/day for 90 days)
Number of subjects: 26
Study 10326743 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 26
Study 10326743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 26
Study 7927099 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (100 mg, n = 35)
Number of subjects: 71
Study 7927099 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (50 mg, n = 36)
Number of subjects: 71
Study 2685177 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass operation
Number of subjects: 838
Study 2685177 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 838
Study 131310 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin solution
Number of subjects: 0
Study 131310 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin solution
Number of subjects: 0
Study 131310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (solvent only)
Number of subjects: 0
Study 31823345 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVA with unequal randomization
Number of subjects: 0
Study 31823345 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust sandwich variance estimators
Number of subjects: 0
Study 29473975 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF + RBV for 8 weeks
Number of subjects: 82
Study 29473975 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF for 12 weeks
Number of subjects: 82
Study 29473975 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF + RBV for 12 weeks
Number of subjects: 82
Study 29473975 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF without RBV for 12 weeks
Number of subjects: 82
Study 29473975 — intervention group
Group type: EXPERIMENTAL
Intervention: EBR/GZR + SOF for 16 weeks
Number of subjects: 82
Study 28716117 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Prevention@Work intervention
Number of subjects: 0
Study 28716117 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list design)
Number of subjects: 0
Study 25459098 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR) - 15 mcg ethinyl estradiol/150 mcg etonogestrel
Number of subjects: 132
Study 25459098 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (COC) - 20 mcg ethinyl estradiol/100 mcg levonorgestrel
Number of subjects: 132
Study 24039738 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (5 mg)
Number of subjects: 109
Study 24039738 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 mg)
Number of subjects: 109
Study 21463508 — intervention group
Group type: EXPERIMENTAL
Intervention: SODIS promotion campaign
Number of subjects: 0
Study 21463508 — intervention group
Group type: EXPERIMENTAL
Intervention: SODIS promotional events participation
Number of subjects: 0
Study 21463508 — intervention group
Group type: EXPERIMENTAL
Intervention: Household characteristics (women included)
Number of subjects: 0
Study 21463508 — intervention group
Group type: EXPERIMENTAL
Intervention: Household characteristics (latrine ownership)
Number of subjects: 0
Study 21463508 — intervention group
Group type: EXPERIMENTAL
Intervention: Household characteristics (presence of severely wasted children)
Number of subjects: 0
Study 18071814 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered signal-averaged P-wave duration measurement during pneumoperitoneum (PP)
Number of subjects: 20
Study 18071814 — intervention group
Group type: COMPARATOR
Intervention: Standard ECG measurement
Number of subjects: 20
Study 16492206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30-45 mg/day
Number of subjects: 283
Study 16492206 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide 80-320 mg/day
Number of subjects: 283
Study 12944338 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrichment program (ages 3-5 years)
Number of subjects: 83
Study 12944338 — intervention group
Group type: COMPARATOR
Intervention: Usual community conditions (control group)
Number of subjects: 83
Study 11098021 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogues (6 months down-regulation)
Number of subjects: 18
Study 11098021 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic laser diathermy
Number of subjects: 18
Study 9330023 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 20
Study 9330023 — intervention group
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Number of subjects: 20
Study 9330023 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 8355859 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg tid
Number of subjects: 127
Study 8355859 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg tid
Number of subjects: 127
Study 8355859 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg tid
Number of subjects: 127
Study 8355859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 2980323 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol
Number of subjects: 0
Study 2980323 — intervention group
Group type: COMPARATOR
Intervention: Sodium iothalamate (Control)
Number of subjects: 0
Study 2980323 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (Control)
Number of subjects: 0
Study 31568094 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted screw insertion
Number of subjects: 135
Study 31568094 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy-assisted screw insertion
Number of subjects: 135
Study 29627257 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-arm-assisted UKA
Number of subjects: 139
Study 29627257 — intervention group
Group type: COMPARATOR
Intervention: Conventional UKA
Number of subjects: 139
Study 25503711 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim training with inspiratory muscle training (N=8)
Number of subjects: 24
Study 25503711 — intervention group
Group type: COMPARATOR
Intervention: Swim training only (N=8)
Number of subjects: 24
Study 25503711 — intervention group
Group type: COMPARATOR
Intervention: Swim training with sham‐inspiratory muscle training (N=8)
Number of subjects: 24
Study 25681312 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 1434
Study 25681312 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 1434
Study 23053685 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular-focused treatment
Number of subjects: 22
Study 23053685 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 22
Study 22166673 — intervention group
Group type: EXPERIMENTAL
Intervention: No sedation
Number of subjects: 140
Study 22166673 — intervention group
Group type: COMPARATOR
Intervention: Sedation with daily interruption
Number of subjects: 140
Study 19092340 — intervention group
Group type: COMPARATOR
Intervention: TAC-PL (Tacrolimus - Placebo)
Number of subjects: 156
Study 19092340 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-ST (Tacrolimus - Short-term Steroid)
Number of subjects: 156
Study 16441532 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with a rheumatology clinical nurse specialist
Number of subjects: 71
Study 16441532 — intervention group
Group type: COMPARATOR
Intervention: Outpatient staff nurse for safety monitoring only
Number of subjects: 71
Study 12900683 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine + CHO (10 g L-arginine with 70 g carbohydrate)
Number of subjects: 0
Study 12900683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine + CHO)
Number of subjects: 0
Study 10879440 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (BR-Tr)
Number of subjects: 9
Study 10879440 — intervention group
Group type: COMPARATOR
Intervention: Non-training control (BR-Cont)
Number of subjects: 9
Study 9109106 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 17
Study 9109106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9109106 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP administration
Number of subjects: 17
Study 8211009 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 18
Study 8211009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 18
Study 8211009 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 4017679 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched oxygen for either six hours or 20 minutes prior to testing
Number of subjects: 10
Study 4017679 — intervention group
Group type: COMPARATOR
Intervention: Room air for either six hours or 20 minutes prior to testing
Number of subjects: 10
Study 29490012 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, moderate-intensity physical activity (PA) program consisting of center-based (twice/week) and home-based (three to four times per week) aerobic, resistance, and flexibility training
Number of subjects: 1635
Study 29490012 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE) program combined with upper extremity stretching
Number of subjects: 1635
Study 26858193 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus initiated at 4.5 mg/m2/day, titrated to blood trough levels of 5-15 ng/mL.
Number of subjects: 18
Study 24853308 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 2500
Study 24853308 — intervention group
Group type: COMPARATOR
Intervention: Control (no IPT)
Number of subjects: 2500
Study 24453831 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (DD) of aspirin and clopidogrel (n = 58)
Number of subjects: 116
Study 24453831 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (SD) of aspirin and clopidogrel (n = 58)
Number of subjects: 116
Study 24453831 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose (DD) of aspirin and clopidogrel
Number of subjects: 116
Study 21112451 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intervention (HII; 30-min motivational interview plus seven routine telephone calls after hospital discharge)
Number of subjects: 237
Study 21112451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Intervention (LII; 15-min counseling about the benefits of quitting)
Number of subjects: 237
Study 21112451 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 237
Study 18256968 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy methods (brief interventions and cognitive-behavioral therapy)
Number of subjects: 400000
Study 18256968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological approaches (disulfiram, acamprosate, naltrexone)
Number of subjects: 400000
Study 15870437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense ICE chemotherapy (4-week interval)
Number of subjects: 318
Study 15870437 — intervention group
Group type: COMPARATOR
Intervention: Standard ICE chemotherapy (2-week interval)
Number of subjects: 318
Study 13678872 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg once daily
Number of subjects: 12218
Study 13678872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12218
Study 10202683 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium (IPM/CS)
Number of subjects: 148